Enorama Pharma AB (publ) (ERMA.ST)
SEK 2.95
(3.15%)
SEK 2.95
(3.15%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -1.61 SEK | 69.77% |
| 2022 | -4.40 SEK | -15.79% |
| 2021 | -3.80 SEK | -7.34% |
| 2020 | -3.54 SEK | 4.07% |
| 2019 | -3.69 SEK | -19.81% |
| 2018 | -3.08 SEK | -69.23% |
| 2017 | -1.82 SEK | 4.71% |
| 2016 | -1.91 SEK | -1023.53% |
| 2015 | -0.17 SEK | -3107.55% |
| 2014 | -0.01 SEK | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q2 | -0.14 SEK | 26.32% |
| 2024 Q1 | -0.19 SEK | 34.48% |
| 2023 Q1 | -0.33 SEK | 74.22% |
| 2023 Q3 | -0.32 SEK | -28.0% |
| 2023 Q2 | -0.25 SEK | 24.24% |
| 2023 FY | - SEK | 69.77% |
| 2023 Q4 | -0.29 SEK | 9.38% |
| 2022 Q3 | -1.06 SEK | 25.35% |
| 2022 Q4 | -1.28 SEK | -20.75% |
| 2022 FY | - SEK | -15.79% |
| 2022 Q1 | -1.42 SEK | -1756.21% |
| 2022 Q2 | -1.42 SEK | 0.0% |
| 2021 Q3 | -1.33 SEK | -49.44% |
| 2021 FY | - SEK | -7.34% |
| 2021 Q4 | -0.08 SEK | 94.25% |
| 2021 Q1 | -1.02 SEK | 53.42% |
| 2021 Q2 | -0.89 SEK | 12.75% |
| 2020 FY | - SEK | 4.07% |
| 2020 Q2 | -0.34 SEK | 59.04% |
| 2020 Q1 | -0.83 SEK | 39.86% |
| 2020 Q3 | -0.88 SEK | -158.82% |
| 2020 Q4 | -2.19 SEK | -148.86% |
| 2019 Q3 | -1.43 SEK | -83.33% |
| 2019 Q4 | -1.38 SEK | 3.5% |
| 2019 FY | - SEK | -19.81% |
| 2019 Q1 | -0.86 SEK | 37.68% |
| 2019 Q2 | -0.78 SEK | 9.3% |
| 2018 Q2 | -0.65 SEK | -3.17% |
| 2018 FY | - SEK | -69.23% |
| 2018 Q4 | -1.38 SEK | -97.14% |
| 2018 Q3 | -0.70 SEK | -7.69% |
| 2018 Q1 | -0.63 SEK | 7.35% |
| 2017 Q3 | -0.48 SEK | -17.07% |
| 2017 Q1 | -0.35 SEK | 16.67% |
| 2017 Q2 | -0.41 SEK | -17.14% |
| 2017 FY | - SEK | 4.71% |
| 2017 Q4 | -0.68 SEK | -41.67% |
| 2016 Q1 | -0.72 SEK | -442.86% |
| 2016 FY | - SEK | -1023.53% |
| 2016 Q4 | -0.42 SEK | -68.0% |
| 2016 Q3 | -0.25 SEK | 67.53% |
| 2016 Q2 | -0.77 SEK | -6.94% |
| 2015 FY | - SEK | -3107.55% |
| 2015 Q2 | -0.13 SEK | 23.53% |
| 2015 Q3 | -0.07 SEK | 46.92% |
| 2015 Q4 | 0.21 SEK | 404.35% |
| 2015 Q1 | -0.17 SEK | 0.0% |
| 2014 FY | - SEK | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| AcuCort AB | -0.16 SEK | -906.25% |
| AlzeCure Pharma AB (publ) | -0.60 SEK | -168.333% |
| BioGaia AB (publ) | 3.62 SEK | 144.475% |
| Enzymatica AB (publ) | -0.28 SEK | -475.0% |
| Gabather AB (publ) | -0.65 SEK | -147.692% |
| Klaria Pharma Holding AB (publ.) | -0.36 SEK | -347.222% |
| Moberg Pharma AB (publ) | -1.33 SEK | -21.053% |
| Nanexa AB (publ) | -1.09 SEK | -47.706% |
| Newbury Pharmaceuticals AB (publ) | -0.72 SEK | -123.611% |
| ODI Pharma AB | 0.02 SEK | 6980.342% |
| Orexo AB (publ) | -3.73 SEK | 56.836% |
| Probi AB (publ) | 1.48 SEK | 208.784% |
| Swedencare AB (publ) | 0.37 SEK | 535.135% |
| Swedish Orphan Biovitrum AB (publ) | 7.47 SEK | 121.553% |
| Toleranzia AB | -0.06 SEK | -2775.0% |
| Vivesto AB | -0.74 SEK | -117.568% |